OWise Breast Cancer

OWise Breast Cancer Download the OWise breast cancer support app for free here: https://owi.se/dl 💜 https://linktr.ee/OWisebreast

04/09/2026

New research suggests some breast cancer survivors whose heart function was affected by HER2-targeted treatment may not need to stay on heart medication for life 💜

In a small trial of 90 women whose heart function had recovered:

🔹 46 gradually stopped their heart medication, while 44 continued

🔹 After 1 year, 98% of those who stopped had no decline in heart function

🔹 1 woman experienced a decline, which improved after restarting medication

🔹 No heart failure symptoms or hospital admissions were reported

The study was small and follow-up was only 1 year, so more research is still needed. But the findings suggest that for some people, lifelong heart medication may not always be necessary once heart function has recovered 🙌

Any changes to heart medication should only be made with medical supervision and ongoing monitoring ‼️

👉 Share this to help spread awareness 💜

Source: British Heart Foundation. “Breast cancer survivors could avoid lifelong heart medication.” Study published in the European Heart Journal and presented at ESC Congress 2026.

Two people with HR+/HER2- metastatic breast cancer could be eligible for Gedatolisib treatment, but one mutation changes...
04/09/2026

Two people with HR+/HER2- metastatic breast cancer could be eligible for Gedatolisib treatment, but one mutation changes its FDA status. Here’s why…👇

Gedatolisib is already FDA approved for some people with HR+/HER2− metastatic breast cancer, but PIK3CA status still matters 💜

In VIKTORIA-1 researchers looked separately at people with and without a PIK3CA mutation 🧬

For people without a PIK3CA mutation, gedatolisib + fulvestrant, with or without palbociclib, is already FDA approved in the US ✅

For people with a PIK3CA mutation, VIKTORIA-1 also showed promising results, and an application has now been submitted to the FDA to expand the approval to this group 💡

This is why genomic testing can be so important in metastatic breast cancer,
one mutation can change which targeted treatments may be available 🔍

Save this or share with someone navigating HR+/HER2− metastatic breast cancer 💜

For more on metastatic HR+ treatment options read this 👉 https://owise.uk/secondary-hormone-positive/

03/09/2026

Gedatolisib is already FDA approved for some people with HR+/HER2− metastatic breast cancer, but PIK3CA status still matters 💜

In VIKTORIA-1 researchers looked separately at people with and without a PIK3CA mutation 🧬

For people without a PIK3CA mutation, gedatolisib + fulvestrant, with or without palbociclib, is already FDA approved in the US ✅

For people with a PIK3CA mutation, VIKTORIA-1 also showed promising results, and an application has now been submitted to the FDA to expand the approval to this group 💡

This is why genomic testing can be so important in metastatic breast cancer,
one mutation can change which targeted treatments may be available 🔍

Save this or share with someone navigating HR+/HER2− metastatic breast cancer 💜

For more on metastatic HR+ treatment options read this 👉 https://owise.uk/secondary-hormone-positive/

02/09/2026

Painful s*x, vaginal burning and recurring UTIs can feel like separate problems, but after breast cancer treatment they may be connected 💜

👉 Read our full article ‘Urogenital Side Effects of Breast Cancer Treatment: Symptoms and Management’ here 🔗 https://owise.uk/urogenital-problems-and-breast-cancer/

01/09/2026

Feel it on the first 💜

This is your reminder to check your chest today 🙏

Send this to someone to make sure they do too 🫶

For more info on changes to look out for head to the blog ‘Breast Cancer: Signs and Diagnosis’ here 🔗 https://owise.uk/breast-cancer-signs-and-diagnosis/

31/08/2026

Metastatic Mondays: Updates in metastatic breast cancer💜

New trial results suggest that tucatinib could help delay disease progression in people with HER2-positive metastatic breast cancer🙏

The HER2CLIMB-05 trial looked at adding tucatinib to trastuzumab + pertuzumab maintenance treatment🔬

What did the trial find?📊

Patients receiving tucatinib had a median of 24.9 months before their cancer grew or spread ➡️ This compared with 16.3 months without tucatinib💊

For people with brain metastases, progression-free survival was 8.5 months with tucatinib vs. 4.3 months without⏳

These results suggest tucatinib may help delay cancer progression, including for people living with brain metastases🧠

For National Grief Awareness Day we’re revisiting Carly Moosah’s words on a part of breast cancer that isn’t always talk...
30/08/2026

For National Grief Awareness Day we’re revisiting Carly Moosah’s words on a part of breast cancer that isn’t always talked about, grief 💜

👉 Read Carly’s full blog ‘Breast Cancer and Grief: A Path to Healing’ here 🔗 https://owise.uk/breast-cancer-and-grief-a-path-to-healing/

29/08/2026

Side effects can be easy to brush off, especially when you’re already dealing with everything else that comes with breast cancer treatment 💜

But keeping your care team updated on what you’re experiencing can help them understand how treatment is affecting you and whether anything needs to be managed differently 🙏

This includes symptoms or side effects that might feel small, embarrassing or not “important enough” to mention. If something has changed or is affecting your day-to-day life, it’s worth bringing up 📝

Read the full Self Advocacy and Breast Cancer blog here 💜👉 https://owise.us/read/self-advocacy-and-breast-cancer?mtm_campaign=selfadvocacy&mtm_source=facebook%E2%80%A6

28/08/2026

For HER2+ early breast cancer treatment doesn’t always follow the same order 💜

Some people have neoadjuvant treatment before surgery, while others have surgery first and adjuvant treatment afterwards. Which approach is recommended can depend on factors including the stage of the cancer, tumour size and whether lymph nodes are involved.

For more information on early HER2 breast cancer treatment head over to the blog ‘It’s all about HER-positive breast cancer’ 💜 👉 https://owise.uk/her2/

27/08/2026

Feel like no one takes your side effects seriously?💜

Use the OWise app to track what’s changing so you can communicate with your care team about what’s going on so you can get the support you need 🙏

🔗 Try the app here 💜 https://owi.se/dl

Address

London

Website

, , ,

Alerts

Be the first to know and let us send you an email when OWise Breast Cancer posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to OWise Breast Cancer:

Shortcuts

Share

Category